Management is awaiting for St Jude Children's Research Hospital to release the second part of the study of Paxalisib (GDC-0084) in DIPG. According to management's milestone estimate, the provisional interim data is now due. Maybe there are negotiations underway, with regards to the ASX RELEASE ON 7 August 2020, US FDA GRANTS RARE PEDIATRIC DISEASE DESIGNATION (RPDD)TO PAXALISIB FOR DIPG?
This is the release of the first stage on 12 September 2019.